In a bid to combat obesity and unemployment, the UK govt is collaborating with Eli Lilly, which will invest £279 mn in a ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with ...

Eli Lilly, the US pharmaceutical giant behind weight-loss drugs like Zepbound and Mounjaro, has announced a strategic ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its ...

Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...

While artificial intelligence (AI) has been one of the hottest investing trends, GLP-1 weight loss drugs are a close second.